Literature DB >> 24853787

Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany.

Dieter Hörsch1, Kurt W Schmid, Martin Anlauf, Kaid Darwiche, Tim Denecke, Richard P Baum, Christine Spitzweg, Christian Grohé, Norbert Presselt, Christian Stremmel, David F Heigener, Monika Serke, Thomas Kegel, Marianne Pavel, Cornelius F Waller, Karl-Matthias Deppermann, Rudolf Arnold, Rudolf M Huber, Matthias M Weber, Hans Hoffmann.   

Abstract

Neuroendocrine tumors (NETs; syn. carcinoid tumors) are highly or moderately differentiated neoplasms. They comprise a large variety of rare and heterogeneous tumors with an estimated incidence of 3-5/100,000/year. They can arise in virtually every internal organ, but mainly occur in the gastroenteropancreatic and bronchopulmonary systems. Around 25% of the NETs are localized in the bronchopulmonary system. Approximately 2% of all lung tumors are NETs. According to the World Health Organization (WHO) classification of lung tumors, bronchopulmonary NETs are subdivided into typical carcinoids (TCs) and atypical carcinoids (ACs). The parameter with the highest impact on NET behavior and prognosis is the histological classification and staging according to the tumor/node/metastasis (TNM) system. The diagnosis of NETs is established by histological examination and the immunohistochemical detection of general neuroendocrine markers, such as chromogranin A (CgA) and synaptophysin. Serum markers and the use of functional imaging techniques are important additive tools to establish the diagnosis of a NET. The only curative option for lung NETs is complete surgical resection. Beyond that, the currently available interdisciplinary therapeutic options are local ablation, biotherapy (somatostatin analogues), or chemotherapy. New therapeutic options such as peptide receptor radionuclide therapy (PRRT) and molecularly targeted therapies achieve promising results and are under further evaluation. This report is a consensus summary of the interdisciplinary symposium 'Neuroendocrine Tumors of the Lung and of the Gastroenteropancreatic System (GEP NET) - Expert Dialogue' held on February 25-26, 2011 in Weimar, Germany. At this conference, a panel of 23 German experts shared their knowledge and exchanged their thoughts about research, diagnosis, and clinical management of NETs, whereby special attention was paid to NETs of the respiratory tract.

Entities:  

Mesh:

Year:  2014        PMID: 24853787     DOI: 10.1159/000362430

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN: 2296-5270            Impact factor:   2.825


  20 in total

1.  Do we really care about incidental lung nodules?-Review of atypical lung carcinoid and a proposal for systematic patient follow up.

Authors:  Henal Motiwala; Itisha Bansal; Pradeep Goyal; Olena Dorokhova; Yogesh Kumar; Thomas D Olsavsky; Albert DiMeo; Nishant Gupta
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement.

Authors:  Na Liu; Jingjing Wang; Xiao Fu; Xiaoqiang Zheng; Huan Gao; Tao Tian; Zhiping Ruan; Yu Yao
Journal:  Cancer Biol Ther       Date:  2019-09-27       Impact factor: 4.742

3.  Driver Gene Mutations in Primary Carcinoids of the Lung: Who Are the Best Candidates for Genetic "Next-Generation Sequencing"?

Authors:  Filippo Lococo; Alessia Ciarrocchi
Journal:  Lung       Date:  2015-05-26       Impact factor: 2.584

4.  Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.

Authors:  P Lecomte; C Binquet; M Le Bras; A Tabarin; C Cardot-Bauters; F Borson-Chazot; C Lombard-Bohas; E Baudin; B Delemer; M Klein; B Vergès; T Aparicio; E Cosson; A Beckers; Ph Caron; O Chabre; Ph Chanson; H Du Boullay; I Guilhem; P Niccoli; V Rohmer; J Guigay; C Vulpoi; J Y Scoazec; P Goudet
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

Review 5.  Management of pulmonary neuroendocrine tumors.

Authors:  Robert A Ramirez; Aman Chauhan; Juan Gimenez; Katharine E H Thomas; Ioni Kokodis; Brianne A Voros
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

Review 6.  The Diagnosis and Treatment of Bronchopulmonary Carcinoid.

Authors:  Jussuf T Kaifi; Gian Kayser; Juri Ruf; Bernward Passlick
Journal:  Dtsch Arztebl Int       Date:  2015-07-06       Impact factor: 5.594

Review 7.  Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.

Authors:  Edward M Wolin
Journal:  Oncologist       Date:  2015-08-25

8.  Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.

Authors:  Claudia Pivonello; Panagoula Rousaki; Mariarosaria Negri; Maddalena Sarnataro; Maria Napolitano; Federica Zito Marino; Roberta Patalano; Maria Cristina De Martino; Concetta Sciammarella; Antongiulio Faggiano; Gaetano Rocco; Renato Franco; Gregory A Kaltsas; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

Review 9.  [Pulmonary carcinoids and carcinoids of the small intestine].

Authors:  K S Winter; C J Auernhammer; A Todica; J Ricke; C Cyran
Journal:  Radiologe       Date:  2019-11       Impact factor: 0.635

10.  Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience.

Authors:  Fabio Minutoli; Davide Cardile; Riccardo Laudicella; Antonio Vento; Benedetta Pagano; Sergio Baldari
Journal:  Nucl Med Mol Imaging       Date:  2021-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.